



REVA MEDICAL PRESENTS INITIAL DATA FROM MOTIV BTK PILOT TRIAL AT THE LEIPZIG INTERVENTIONAL COURSE 2021

San Diego, California (Friday, 29 January 2021) – REVA Medical, LLC. (“REVA” or the “Company”), a leader in bioresorbable polymer technologies for vascular applications, presented initial data from a post market study of the Company’s MOTIV below the knee (BTK) scaffold.

Dr. Michel J. Bosiers from the St. Franziskus-Hospital Muenster, Germany presented an initial safety and performance study of REVA’s MOTIV sirolimus-eluting bioresorbable scaffold in patients with CLI and BTK lesions. Dr. Bosiers presented the study at the Leipzig Interventional Course (LINC) 2021. Presentation material delivered at the conference is available from LINC and at REVA’s website: www.revamedical.com.

About REVA Medical

REVA Medical is a medical device company focused on the development and commercialization of bioresorbable polymer technologies for vascular applications. The Company’s products include MOTIV bioresorbable scaffolds for the treatment of peripheral artery disease, Fantom and Fantom Encore bioresorbable vascular scaffolds for the treatment of coronary artery disease, and TyroSphere embolic beads. REVA is based in San Diego, California. More information can be found at REVA’s website: www.revamedical.com.

Fantom, Fantom Encore, and MOTIV have CE Mark only. Fantom, Fantom Encore, and MOTIV are available in select countries in Europe and the Middle East. Fantom, Fantom Encore, MOTIV, and TyroSphere are not available in the U.S. or other countries that do not accept CE Mark. Fantom, Fantom Encore, MOTIV, TyroSphere, and Tyrocore are trademarks of REVA Medical, LLC.

Forward-Looking Statements

This announcement contains or may contain forward-looking statements that are based on management's beliefs, assumptions, and expectations and on information currently available to management. All statements that are not statements of historical fact, including those statements that address future operating plans or performance and events or developments that may occur in the future, are forward-looking statements, such as those statements regarding the projections and timing surrounding commercial operations and sales, clinical trials, pipeline product development, and future financings. No undue reliance should be placed on forward-looking statements. Although management believes forward-looking statements are reasonable as and when made, forward-looking statements are subject to a number of risks and uncertainties that may cause actual results to vary materially from those expressed in forward-looking statements. Any forward-looking statements in this announcement speak only as of the date when made. REVA does not assume any obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise.